According to a World Health Organization panel on Friday by a World Health Organization panel, Gilead’s drug remdesivir is not recommended for patients hospitalized with Corona 19. This is because there is no evidence to improve survival or reduce the need for ventilation, no matter how sick you are.
“The panel found a lack of evidence that Rem Desivir improved critical outcomes for patients, such as reduced mortality, the need for mechanical ventilation, and time for clinical improvement,” said the guidelines.
This advice is another frustration with the drug, which has garnered worldwide attention as a potentially effective treatment for COVID-19 in the summer, when early clinical trials showed little promise.
Read: Pfizer Bioentech COVID-19 Vaccine Delivery May Start By This Month’If Everything Goes Well’
At the end of October, Gilead lowered its 2020 earnings forecast due to lower-than-expected demand and difficulty in forecasting remdesivir sales.
Antiviral drugs are currently one of two drugs approved worldwide to treat COVID-19 patients, but a large WHO-led trial known as a solidarity trial has shown little or no effect on mortality or duration on the 28th of the past month. Shredded. Hospital admission for COVID-19 patients.
This drug was one of the drugs used to treat U.S. President Donald Trump’s coronavirus infection, and previous studies have shown it to reduce recovery time. Approved or approved for use as a treatment for COVID-19 in more than 50 countries.
Gilead questioned the outcome of the solidarity trial.
The WHO’s Guideline Development Group (GDG) panel said it made recommendations based on a review of evidence that included data from four internationally randomized trials involving more than 7,000 patients hospitalized with COVID-19.
After reviewing the evidence, the panel concluded that administration is expensive, as it should be administered intravenously, and that the complex remdesivir did not significantly affect the patient’s mortality or other significant outcomes.
“Particularly considering the cost and resource impacts associated with remdesivir, the panel felt responsible for demonstrating evidence of efficacy not established by currently available data.”
The latest WHO advice comes after one of the world’s top organizations representing intensive care unit doctors told them that antiviral drugs should not be used for COVID-19 patients in intensive care units.
The WHO’s non-binding recommendations are part of the so-called “Guidelines for Living” project, designed to provide guidance that can help doctors make clinical decisions about patients in rapidly changing situations, such as the COVID-19 pandemic. . Guidelines can be updated and reviewed as new evidence and information emerge.
However, the panel supported continued enrollment in clinical trials evaluating remdesivir in COVID-19 patients, which “should provide greater certainty for specific patient groups.”
This advisory could raise further questions as to whether the European Union requires 500,000 courses of antiviral drugs worth 1 billion euros ordered last month.